ARID1B and non-small cell lung carcinoma: Furthermore, we found a correlation between ARID1B alteration (any form of non-synonymous mutation in ARID1B, classifies the patient as belonging to the ARID1B-altered group) and bone metastasis in NSCLC patients, with a lower incidence of bone metastasis observed in patients with ARID1B mutation (Fig. 1C).